Sarepta, Replimmune, Capricor rise as FDA's biologics head departs
Source: SeekingAlpha
2025-07-30 10:27:30 ET
More on Sarepta, Capricor, etc.
- Sarepta Therapeutics: Beaten Down, But Not Out
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
- FDA vaccines head, chief medical officer Vinay Prasad departs agency
- Sarepta upgraded to Neutral at J.P. Morgan, Outperform at Oppenheimer
Read the full article on Seeking Alpha
For further details see:
Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
Roche Holding Ltd
NASDAQ: RHHBF
RHHBF Trading
-6.23% G/L:
$436.044 Last:
31 Volume:
$411.36 Open:
RHHBF Latest News
RHHBF Stock Data
$362,551,633,888
800,578,845
N/A
474
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
